REGULATORY

• MHLW Withdraws Sakigake Tag for Takeda’s TAK-925
  September 17, 2025

• Health Minister Avoids Speculation on Impact of US Drug Price Cuts
  September 16, 2025

• Tensions Flare at Chuikyo over Premiums for Generic Dispensing
  September 16, 2025

• Motegi Calls for Lowering Generic Prices by Consolidation: LDP Race
  September 11, 2025

• Lawmakers Urge Chuikyo to Respect Public-Private Council Views
  September 11, 2025

• MHLW Panel Urges Tighter Scrutiny of GLP-1 “Weight Loss” Ads
  September 11, 2025

• JPMA Pushes for Mandatory Collection of Medical Data, JMA Fires Back
  September 11, 2025

• Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
  September 11, 2025

• Generics to Be Exempt from Tariffs under US-Japan Deal: Govt Officials
  September 10, 2025

• Label Revisions Ordered for Antihypertensives, Adalimumab, I/O Meds, and More
  September 10, 2025

• Japan Panel Approves 5 COVID Vaccines for NIP Use from October
  September 9, 2025

• MHLW Seeks to Raise Quality of Prefectural Generic GMP Inspections
  September 8, 2025

• MHLW Panel Backs Draft ARI Prevention Guidelines, Due Out November
  September 5, 2025

• Japan Kicks Off Debate on Medical Data Use Framework, Eyes 2027 Legislation
  September 4, 2025

• MHLW Seeks Sponsor for Drug Loss Product Trifarotene
  September 4, 2025

• Japan Govt Council Gathers Views to Shape National MCM Strategy
  September 4, 2025

• Japan Panel Supports Plan to Prioritize MCM Development by Need and Feasibility
  September 4, 2025

• Generics Surge in FY2024 on New Out-of-Pocket Rule for Long-listed Drugs
  September 3, 2025

• Pharma Groups Press Pricing Reform at First Public-Private WG Meeting
  September 2, 2025

• Japan Panel Clears Izervay, Nexletol for Approval; Eylea Biosimilars Edge Ahead Too
  September 1, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• …
• Next ›
• 最終 »